Strides Pharma Science Ltd News

Strides Pharma jumps 12% on healthy Q3 operational performance

The management said Strides continues to deliver a strong performance in Q3FY26 with growth primarily driven by the Other Regulated Markets and Growth Markets.

Strides Pharma Q3FY26 results: Net profit doubles to ₹208.12 cr

Strides Pharma Science Ltd on Friday reported over two-fold rise in consolidated net profit at Rs 208.12 crore in the third quarter ended December 31, 2025 on the back of robust sales growth and one time income on sale of property. The company had posted a consolidated net profit of Rs 90.04 crore in the corresponding quarter last fiscal, Strides Pharma Science Ltd said in a regulatory filing. Consolidated revenue from operations in the third quarter stood at Rs 1,194.65 crore as against Rs 1,153.67 crore in the year-ago period, it added. Total expenses in the quarter under review were higher at Rs 1,052.7 crore as compared to Rs 1,043.96 crore in the same period a year ago, the company said. The company said during the third quarter it sold its investment property consisting of land and building for a consideration of Rs 112.87 crore and recorded a profit of Rs 102.14 crore as other income. Commenting on the performance, Strides Pharma Science MD & Group CEO, Badree Komandur, ...

Strides Pharma spurts 15%, hits all-time high on strong Q2 performance

Strides Pharma business outlook, in Q2 earnings update the company said the expansion of product portfolio and new customer acquisitions to drive growth.

Strides Pharma Q2FY26 results: Net profit jumps 82% to ₹131.5 crore

Strides Pharma Science Ltd on Friday reported an 82 per cent jump in consolidated net profit at Rs 131.52 crore in the second quarter ended September 30, 2025 on the back of strong revenue growth in 'other regulated markets' and lower expenses. The company had posted a consolidated net profit of Rs 72.3 crore in the corresponding period last fiscal, Strides Pharma Science said in a regulatory filing. Consolidated revenue from operations in the second quarter stood at Rs 1,220.83 crore as compared to Rs 1,166.93 crore in the year-ago period, it added. Total expenses in the quarter under review stood at Rs 1,085.03 crore as compared to Rs 1,104.61 crore in the same period last fiscal, the company said. Commenting on the performance, Strides Pharma Science MD & Group CEO, Badree Komandur said, "Strides continues to deliver a strong performance in Q2FY26, with growth primarily driven by the 'other regulated markets'." In an investor presentation, the company said in Q2 FY26 'other ...

Strides enters into product partnership with Kenox for nasal spray

Strides Pharma Science Ltd on Monday said its Singapore-based subsidiary has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc, which will strengthen the pipeline of nasal spray products across diverse therapeutic areas. Strides Pharma Global Pte, Singapore will collaborate with Kenox on the development and filing of multiple nasal spray products for the US market across diverse therapeutic indications, a joint statement said. The collaboration aims to accelerate affordable, high-quality medicines for patients in the US. However, it also mentioned that specific product details remain confidential at this stage. Kenox is a contract development and manufacturing company specialising in Orally Inhaled and Nasal Drug Products (OINDPs). Strides Pharma Science Executive Director Business Development Aditya Kumar said: "Weannounce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space. Nasal sprays have ...